NASDAQ · APEN
Apollo Endosurgery, Inc.
$10.00$0.00 (0.0%)
Apollo Endosurgery, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
Loading market information…
NASDAQ · GRALV · USD
Stock price
Quote as of Jun 24, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GRAIL, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 20.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms. Additionally, it provides DAC, a diagnostic assistance tool aimed at accelerating the diagnostic process for patients with a clinical suspicion of cancer. Beyond initial detection and diagnosis, GRAIL is also engaged in developing tests for minimal residual disease (MRD) and other post-treatment monitoring applications. Established in 2015, the company originally operated as PSC15, Inc. before rebranding as GRAIL, LLC in January 2016. Headquartered in Menlo Park, California, GRAIL, LLC functions as a subsidiary of Illumina, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$10.00$0.00 (0.0%)
Apollo Endosurgery, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
$5.59-$0.01 (-0.09%)
BioDelivery Sciences International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
$7.02$0.00 (0.0%)
Accolade, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.4% below the high.
$8.16$0.00 (0.0%)
Regulus Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
$8.68$0.00 (0.0%)
Sage Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.26% below the high.
$18.99$0.00 (0.0%)
ZimVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.11% below the high.
$1.43-$0.01 (-0.35%)
Sharecare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
$23.15-$0.36 (-1.53%)
MultiPlan Corporation’s quoted price sits in the upper half of its reported 52-week range, 39.85% below the high.
